Clinical Trial Search

Primary: Clinical Response to High-Dose Interleukin-2 (H-D IL-2) Followed by Low Dose Temozolomide — 17; 4; 0; 1 Participants

Primary: Change in EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) — 11.1; 14.5; 11.5; 12.5 units on a scale — p=0.678

Primary: Change in Traditional Immune Parameters Measurements Using Luminex Assays and Gene Expression Measurement Using Microarray Experiments From Baseline With Influenza A…

Primary: Number of Patients That Have Achieved Complete Remission of Disease — 17; 4 Participants — p=0.0301

Primary: Mean Time From Start of Study Treatment Administration to Recovery of the T4/T1 Ratio to 0.9 — 108.43; 44.73; 6.93; 2.40 minutes

Primary: Participants With Dose-Limiting Toxicities (DLTs) During the Dose-Determining Timeframe (Day 1 - Day 28) — 1; 1; 0 Participants

Primary: Percent Change From Baseline in Fasting Low Density Lipoprotein-Cholesterol (LDL-C) at Day 85 — -55.65; -68.25; -74.00; -5.91 percent change — p=<0.001

Primary: Detected Intraepithelial Neoplasia — 0.2 Number of detected IN

Primary: Time From Start of Administration of Sugammadex or Placebo to Recovery of the Fourth Twitch/First Twitch (T4/T1) Ratio to 0.9 — 82.08; 3.95; 2.48; 2.17 Minutes

Primary: Symptom Assessment in Dry Eye (SANDE) Scores — -38.8; -34.0; -32.2; -31.07 units on a scale — p==0.428

Primary: Leukemia-Free Survival — 6.7; 17.6; 13.9 MONTHS

Primary: Compete Response Rate — 31 participants

Primary: Change From Baseline in 24-hour Urinary Glucose Excretion (UGE) on Day 7 — 40.45; 31.87; 36.27; 19.88 gram (g) — p=0.154

Primary: Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12) — 77.8 Percentage of participants

Primary: Incidence of Subjects Experiencing Treatment Emergent Adverse Events From Baseline Through End of Study — 3; 2; 7; 4 Participants